

### **REMARKS/ARGUMENTS**

Claims 15 and 21-28 are pending in the captioned application. Claims 5 and 23-26 have been allowed, while claims 21 and 22 are withdrawn from further consideration. In a telephone conversation with the Examiner on July 17, 2007, it is confirmed that claims 27 and 28 are pending and allowed as well. Therefore claims 15 and 23-28 have been allowed.

Applicants acknowledge the Examiner's rejoining of claims 23-25. Applicants hereby cancel claims 21 and 22, and reserve the right to prosecute these claims in one or more divisional applications.

The specification has been objected to by the Examiner. The specification contains figures, some of which include amino acid or nucleic acid sequences, while lacking corresponding sequence identifiers for these sequences. In response, Applicants have amended the specification to include a section of Brief Description of the Drawings. Sequence identifiers are included in this section. Support for this section can be found in the figures themselves. Further support can be found in the specification, as follows:

Figure 1: page 2, lines 5-7 from bottom of page;

Figure 2: last two lines of page 4;

Figure 3: page 8, lines 5-6;

Figure 4: page 5, lines 4 -2 from bottom of page;

Figure 5: page 6, lines 3 -2 from bottom of page;

Figures 6 -10, page 7, Section 4, entitled “Uniform termination events”;

Figures 11 -12, page 7, Section 5, entitled “Ability to sequence difficult areas”;

Figure 13, page 8, lines 4-8 from bottom of page;

Figure 14, page 8, lines 1-3 from bottom of page;

Figure 15, page 3, last paragraph;

Figure 16, page 12, lines 8-12;

Figure 17, last paragraph of page 14, and first paragraph of page 15;

Figure 18, page 16, section 3.4, entitled Sequencing Results;

Figure 19, see paragraph bridging pages 19 and 20.

Applicants respectfully submit that these amendments are fairly based on the specification and do not introduce new matter.

A revised Sequence Listing is filed herewith and includes sequences 6 through 16 as found in figures 6 through 13. No new matter is introduced. Applicants respectfully request that this new Sequence Listing replace the originally filed Sequence Listing.

Appl. No. 10/049,358  
Amendment dated August 27, 2007  
Reply to Office action of June 25, 2007

Early and favorable consideration is respectfully requested.

Respectfully submitted,

GE Healthcare Bio-Sciences Corp.

By:



Yonggang Ji  
Reg. No.: 53,073  
Agent for Applicants

GE Healthcare Bio-Sciences Corp.  
800 Centennial Avenue  
P. O. Box 1327  
Piscataway, New Jersey 08855-1327

Tel: (732) 980-2875  
Fax: (732) 457-8463

I hereby certify that this correspondence is being uploaded to the United States Patent and Trademark Office using the Electronic Filing System on August 27, 2007.

Signature:



Name:

Melissa Leck